• IM/Endocrinology

• Pituitary

The research of Ning-Ai Liu, MD, focuses on the developmental and molecular mechanisms underlying hypothalamic-pituitary pathophysiology. Her current research projects seek to identify new therapeutic targets of human pituitary tumor using zebrafish disease model. Major clinical research includes a phase II trial investigating the efficacy and safety of small molecule CDK inhibitor for treatment of Cushing's disease.

• Medical School: Fudan University Shanghai Medical College, 1985
• Internship: Medical College of Georgia, 1997
• Residency: Medical College of Georgia, 1999
• Fellowship: Cedars-Sinai, 2003

• Cancer Institute (Samuel Oschin Comprehensive Cancer Institute)
• Endocrinology
• Department of Neurology and Neurosurgery
• Diabetes Center
• Department of Medicine
• Pituitary Center
• Thyroid Cancer Program
• Cancer
• Medicine
• Adrenal Program
• Thyroid and Parathyroid Disorders

• Ríos Y, Melmed S, Lin S, Liu NA. Zebrafish usp39 mutation leads to rb1 mRNA splicing defect and pituitary lineage expansion. PLoS Genet. 2011;7(1):e1001271.
• Huang H, Lindgren A, Wu X, Liu NA, Lin S. High-throughput screening for bioactive molecules using primary cell culture of transgenic zebrafish embryos. Cell Rep. 2012;2(3):695-704.
• Liu NA, Ren M, Song J, Ríos Y, Wawrowsky K, Ben-Shlomo A, Lin S, Melmed S. In vivo time-lapse imaging delineates the zebrafish pituitary proopiomelanocortin lineage boundary regulated by FGF3 signal. Dev Biol. 2008;319(2):192-200.